Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
NU E Power Corp. Announces Completion of Unwinding its Acquisition of Blu Dot Systems Inc. (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Travere Therapeutics Inc TVTX

Healthcare Biotechnology
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola... see more

Recent & Breaking News (NDAQ:TVTX)

Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Business Wire February 19, 2026

Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

Business Wire February 12, 2026

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire February 11, 2026

Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit

Business Wire February 4, 2026

TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Encourages Investors and Potential Witnesses to Contact Law Firm

GlobeNewswire January 30, 2026

TVTX: Travere Therapeutics Shareholders Should Contact Block & Leviton To Potentially Recover Losses

GlobeNewswire January 27, 2026

Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses

Newsfile January 16, 2026

TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm

Business Wire January 16, 2026

INVESTOR ALERT: Investigation of Travere Therapeutics, Inc. (TVTX) by Holzer & Holzer, LLC

GlobeNewswire January 14, 2026

Travere Therapeutics Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through the Firm's Investigation

ACCESS Newswire January 14, 2026

TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

GlobeNewswire January 13, 2026

SHAREHOLDER ALERT: Travere Therapeutics, Inc. Investigated for Securities Fraud by Block & Leviton; Investors Who Lost Money Should Contact The Firm

GlobeNewswire January 13, 2026

Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS

Business Wire January 13, 2026

Travere Therapeutics Provides Corporate Update and 2026 Outlook

Business Wire January 12, 2026

Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Business Wire January 5, 2026

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 11, 2025

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 10, 2025

Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025

Business Wire November 6, 2025

Travere Therapeutics to Participate at Upcoming Investor Conferences

Business Wire November 4, 2025

Travere Therapeutics Reports Third Quarter 2025 Financial Results

Business Wire October 30, 2025

Podcasts